These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 11410897)

  • 1. Osteoprotegerin inhibits in vitro mouse osteoclast formation induced by joint fluid from failed total hip arthroplasty.
    Kim KJ; Kotake S; Udagawa N; Ida H; Ishii M; Takei I; Kubo T; Takagi M
    J Biomed Mater Res; 2001; 58(4):393-400. PubMed ID: 11410897
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of osteoprotegerin and osteoprotegerin ligand on osteoclast formation by arthroplasty membrane derived macrophages.
    Itonaga I; Sabokbar A; Murray DW; Athanasou NA
    Ann Rheum Dis; 2000 Jan; 59(1):26-31. PubMed ID: 10627423
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Joint fluid from patients with failed total hip arthroplasty stimulates pit formation by mouse osteoclasts on dentin slices.
    Kim KJ; Hijikata H; Itoh T; Kumegawa M
    J Biomed Mater Res; 1998; 43(3):234-40. PubMed ID: 9730060
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects on osteoclast and osteoblast activities in cultured mouse calvarial bones by synovial fluids from patients with a loose joint prosthesis and from osteoarthritis patients.
    Andersson MK; Lundberg P; Ohlin A; Perry MJ; Lie A; Stark A; Lerner UH
    Arthritis Res Ther; 2007; 9(1):R18. PubMed ID: 17316439
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of ex vivo OPG gene therapy in preventing wear debris induced osteolysis.
    Goater JJ; O'Keefe RJ; Rosier RN; Puzas JE; Schwarz EM
    J Orthop Res; 2002 Mar; 20(2):169-73. PubMed ID: 11918293
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Osteoprotegerin produced by osteoblasts is an important regulator in osteoclast development and function.
    Udagawa N; Takahashi N; Yasuda H; Mizuno A; Itoh K; Ueno Y; Shinki T; Gillespie MT; Martin TJ; Higashio K; Suda T
    Endocrinology; 2000 Sep; 141(9):3478-84. PubMed ID: 10965921
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Osteoprotegerin and osteoprotegerin ligand effects on osteoclast formation from human peripheral blood mononuclear cell precursors.
    Shalhoub V; Faust J; Boyle WJ; Dunstan CR; Kelley M; Kaufman S; Scully S; Van G; Lacey DL
    J Cell Biochem; 1999 Feb; 72(2):251-61. PubMed ID: 10022507
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Transforming growth factor beta affects osteoclast differentiation via direct and indirect actions.
    Quinn JM; Itoh K; Udagawa N; Hausler K; Yasuda H; Shima N; Mizuno A; Higashio K; Takahashi N; Suda T; Martin TJ; Gillespie MT
    J Bone Miner Res; 2001 Oct; 16(10):1787-94. PubMed ID: 11585342
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Suppression of osteoprotegerin expression by prostaglandin E2 is crucially involved in lipopolysaccharide-induced osteoclast formation.
    Suda K; Udagawa N; Sato N; Takami M; Itoh K; Woo JT; Takahashi N; Nagai K
    J Immunol; 2004 Feb; 172(4):2504-10. PubMed ID: 14764723
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Arthroplasty membrane-derived fibroblasts directly induce osteoclast formation and osteolysis in aseptic loosening.
    Sabokbar A; Itonaga I; Sun SG; Kudo O; Athanasou NA
    J Orthop Res; 2005 May; 23(3):511-9. PubMed ID: 15885469
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Two distinct cellular mechanisms of osteoclast formation and bone resorption in periprosthetic osteolysis.
    Sabokbar A; Kudo O; Athanasou NA
    J Orthop Res; 2003 Jan; 21(1):73-80. PubMed ID: 12507582
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recombinant adeno-associated virus-mediated osteoprotegerin gene therapy inhibits wear debris-induced osteolysis.
    Ulrich-Vinther M; Carmody EE; Goater JJ; S balle K; O'Keefe RJ; Schwarz EM
    J Bone Joint Surg Am; 2002 Aug; 84(8):1405-12. PubMed ID: 12177271
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum levels of osteoprotegerin and receptor activator of nuclear factor-kappaB ligand as markers of periprosthetic osteolysis.
    Granchi D; Pellacani A; Spina M; Cenni E; Savarino LM; Baldini N; Giunti A
    J Bone Joint Surg Am; 2006 Jul; 88(7):1501-9. PubMed ID: 16818976
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Osteoprotegerin inhibits osteoclast formation and bone resorbing activity in giant cell tumors of bone.
    Atkins GJ; Bouralexis S; Haynes DR; Graves SE; Geary SM; Evdokiou A; Zannettino AC; Hay S; Findlay DM
    Bone; 2001 Apr; 28(4):370-7. PubMed ID: 11336917
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A novel molecular mechanism modulating osteoclast differentiation and function.
    Yasuda H; Shima N; Nakagawa N; Yamaguchi K; Kinosaki M; Goto M; Mochizuki SI; Tsuda E; Morinaga T; Udagawa N; Takahashi N; Suda T; Higashio K
    Bone; 1999 Jul; 25(1):109-13. PubMed ID: 10423033
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of osteoclastogenesis by the secretion of osteoprotegerin in vitro by rat dental follicle cells and its implications for tooth eruption.
    Wise GE; Yao S; Zhang Q; Ren Y
    Arch Oral Biol; 2002 Mar; 47(3):247-54. PubMed ID: 11839361
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gene expression of osteoprotegerin ligand, osteoprotegerin, and receptor activator of NF-kappaB in giant cell tumor of bone: possible involvement in tumor cell-induced osteoclast-like cell formation.
    Huang L; Xu J; Wood DJ; Zheng MH
    Am J Pathol; 2000 Mar; 156(3):761-7. PubMed ID: 10702390
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Over-expression of receptor activator of nuclear factor-kappaB ligand (RANKL), inflammatory cytokines, and chemokines in periprosthetic osteolysis of loosened total hip arthroplasty.
    Wang CT; Lin YT; Chiang BL; Lee SS; Hou SM
    Biomaterials; 2010 Jan; 31(1):77-82. PubMed ID: 19781765
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cross-talk between the interleukin-6 and prostaglandin E(2) signaling systems results in enhancement of osteoclastogenesis through effects on the osteoprotegerin/receptor activator of nuclear factor-{kappa}B (RANK) ligand/RANK system.
    Liu XH; Kirschenbaum A; Yao S; Levine AC
    Endocrinology; 2005 Apr; 146(4):1991-8. PubMed ID: 15618359
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Parathyroid hormone stimulates TRANCE and inhibits osteoprotegerin messenger ribonucleic acid expression in murine bone marrow cultures: correlation with osteoclast-like cell formation.
    Lee SK; Lorenzo JA
    Endocrinology; 1999 Aug; 140(8):3552-61. PubMed ID: 10433211
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.